Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways
elshamy, A., Omran, G., Abd-Alhaseeb, M., HOUSSEN, M. (2024). Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways. EKB Journal Management System, 67(3), 227-234. doi: 10.21608/ejchem.2023.204388.7825
asmaa elshamy; Gamal Omran; Mohammad Abd-Alhaseeb; MAHA HOUSSEN. "Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways". EKB Journal Management System, 67, 3, 2024, 227-234. doi: 10.21608/ejchem.2023.204388.7825
elshamy, A., Omran, G., Abd-Alhaseeb, M., HOUSSEN, M. (2024). 'Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways', EKB Journal Management System, 67(3), pp. 227-234. doi: 10.21608/ejchem.2023.204388.7825
elshamy, A., Omran, G., Abd-Alhaseeb, M., HOUSSEN, M. Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways. EKB Journal Management System, 2024; 67(3): 227-234. doi: 10.21608/ejchem.2023.204388.7825

Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways

Egyptian Journal of Chemistry
Volume 67, Issue 3, March 2024, Page 227-234  XML PDF (670.78 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2023.204388.7825
View on SCiNiTO View on SCiNiTO
Authors
asmaa elshamy1; Gamal Omran2; Mohammad Abd-Alhaseeb3; MAHA HOUSSEN email 4
1Faculty of pharmacy damanhour university
2Biochemistry Department, Faculty of Pharmacy, Damanhour University, Egypt, postal code: 22511
3Pharmacology and Toxicology Department, Faculty of Pharmacy, Damanhour University, Egypt, postal code: 22511
4Biochemistry department faculty of pharmacy Damanhour University
Abstract
Abstract
Breast cancer is the main predisposing factor for female tumor-related death globally, which increases the requirement to investigate the effectiveness of new drug combination strategies. Sorafenib is a multi-kinase inhibitor mainly targeting vascular endothelial growth factor receptor (VEGFR) and Ras/Raf/ Extracellular signal-regulated kinase (ERK) pathway. Stigmasterol is a phytosterol with anticancer activity targeting different oncogenic pathways. This study aimed to examine the antitumor effects of stigmasterol and sorafenib combination against MDA-MB-231 and MCF-7 breast cancer cell lines via assessing their impact on VEGF, VEGFR-2, nuclear factor kappa B (NF-κB), Ki-67, Bcl-2, ERK, and caspase-3. Cytotoxicity was investigated using the MTT assay. VEGF, VEGFR-2, ERK, NF-κB, Bcl-2, and Ki-67 levels were assessed using the ELISA technique. VEGFR-2 gene expression was assessed using the RT-PCR technique, while caspase-3 activity was investigated using the colorimetric technique. Sorafenib and stigmasterol combination reduced the levels of NF-κB, Bcl-2, Ki-67, VEGFR-2, and VEGF-A, whereas the activity of caspase-3 was increased. In addition, MCF-7 showed more favorable results than MDA-MB-231. Stigmasterol and sorafenib combination may be a promising therapeutic regimen for breast cancer treatment through modulation of NF-κB-VEGF/BCL-2 and ERK/Caspase-3 signaling axes crosstalk.
Keywords
Breast cancer; sorafenib; stigmasterol; angiogenesis; apoptosis
Statistics
Article View: 365
PDF Download: 109